A Phase 3 interventional study of Herpes Zoster Vaccine GSK1437173A and Placebo in Herpes Zoster and Herpes Zoster Vaccine, sponsored by GlaxoSmithKline. Completed at 213 sites in 18 countries. Open to participants aged 70 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-04-27.
Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing shingrix in Herpes Zoster — 8 open to participants now, 11 under way, 3 of them phase 3. shingrix · Herpes Zoster.
Among the 46 studies testing shingrix in Herpes Zoster, this one is the 4th largest by enrollment, is one of 4 that started in 2010, is one of 22 in phase 3, and was the 4th registered.
299 studies on the registry are indexed under Herpes Zoster; 55 are open to participants now.
Browse Herpes Zoster studies →8 of the 46 studies testing shingrix in Herpes Zoster are open now, in 5 countries. Recruiting first, the newest first:
GlaxoSmithKline · Sites in Finland
Ages 76+ · Healthy volunteers
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19+
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 18+ · Healthy volunteers
Loyola University · Sites in United States
University of Colorado, Denver · Sites in United States
Ages 18–70
By country, each count listing its studies:
shingrix: first FDA approval 2017 (Shingrix). What it is approved for, and how studies give it, is on its page →
Of the 37 Herpes Zoster studies recruiting now, 26 (70%) set no upper age limit and 6 (16%) stop at 75 or younger; 3 take children under 18; 13 take healthy volunteers.
This study: 70 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 10 · Phase 3 22 · Phase 4 8
First in 2009; this study’s year is marked. 4 started in 2010.
This study's enrollment of 14,819 is above the median of 160 across 247 interventional studies indexed under Herpes Zoster.
Median enrollment 239 across the 46 interventional studies. Of the 32 that completed or were terminated, 27 (84%) have results posted.
This tab as a report to print or save as PDF → With an account.
29 of 46 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
44 studies in Herpes Zoster by GlaxoSmithKline: 3 open now, 5 under way, 1 of them phase 3. Of 39 finished, 34 (87%) have results posted.
Among the 44 studies in Herpes Zoster by GlaxoSmithKline, this one is the 3rd largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2010, is one of 25 in phase 3, and was the 8th registered.
GlaxoSmithKline’s Herpes Zoster studies by the year they started, since 2007.
4 of the studies testing shingrix in Herpes Zoster that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05371080Phase 3GlaxoSmithKlineA Study on the Long-term Efficacy, Safety and Persistence of Immune Response of a Vaccine Against Herpes Zoster in Older Adults | 2027-08-23 |
| NCT05580458National Institute of Allergy and Infectious Diseases (NIAID)Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population | 2027-02-01 |
| NCT06162494Ann & Robert H Lurie Children's Hospital of ChicagoRecombinant Zoster Vaccine in Young Adult Solid Organ Transplant Recipients | 2027-03-31 |
| NCT06569823Dynavax Technologies CorporationSafety and Immunogenicity of an Investigational Herpes Zoster Vaccine (Z-1018) Compared to Shingrix® in Healthy Adults 50 Years of Age and Over | 2027-06 |
Add all 4 to your calendar (.ics) → With an account.
Among the 46 studies testing shingrix in Herpes Zoster, from their registry updates:
Among GlaxoSmithKline’s 44 in Herpes Zoster:
This tab as a report to print or save as PDF → With an account.
The purpose of this observer-blind study is to evaluate the efficacy, safety and immunogenicity of GSK Biologicals' candidate Herpes Zoster (HZ) vaccine in adults aged ≥ 70 years.
Two studies (Zoster-006 [NCT01165177] and Zoster-022 [NCT01165229]) will be conducted concurrently to evaluate efficacy of GSK1437173A vaccine. A pooled analysis of data from both studies combined will be conducted contingent on each study achieving its objectives. This protocol posting also deals with the outcome measures related to the pooled analysis.
This protocol summary has been updated following Protocol Amendment 4 changes to study objectives and endpoints. Pooled analyses of ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) will only be conducted if the primary objective herpes zoster vaccine efficacy (HZ VE) is demonstrated in both ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) separately.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive Herpes Zoster Vaccine GSK1437173A according to a 0, 2-month schedule
Biological: Herpes Zoster Vaccine GSK1437173A
Subjects will receive NaCl solution placebo according to a 0, 2-month schedule
Biological: Placebo
Intramuscular injection
Intramuscular injection.
Number of Subjects With Any Episodes of Herpes Zoster (HZ)
Confirmed HZ cases during the study in the modified total vaccinated cohort (mTVc).
Time frame: During the entire study period (3 to 5 year period following Day 0)
Outcome Measure for the Pooled Analysis of Combined Data From Studies ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229): Number of Subjects With Post-herpetic Neuralgia (PHN)
Incidence of PHN calculated using the mTVc during the entire study period in subjects ≥ 70 years of age (YOA).
Time frame: During the entire study period (3 to 5 year period following Day 0)
Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Confirmed HZ
Occurrence of confirmed HZ during the entire study period in subjects ≥ 70 YOA.
Time frame: During the entire study period (3 to 5 year period following Day 0)
Number of Subjects With Post-herpetic Neuralgia (PHN)
PHN cases in the mTVc.
Time frame: During the entire study period (3 to 5 year period following Day 0)
Number of Days With Severe 'Worst' HZ-associated Pain
Duration of severe 'worst' HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period as measured by the Zoster Brief Pain Inventory (ZBPI) in subjects with confirmed HZ.
Time frame: During the entire study period (3 to 5 year period following Day 0)
Number of Subjects With Confirmed HZ Episode Related Mortality and Hospitalizations
The number of subjects with confirmed HZ related mortality and hospitalizations were tabulated.
Time frame: During the entire study period (3 to 5 year period following Day 0)
Number of Subjects With Overall Mortality and HZ-related Mortality
The number of subjects with overall mortality and HZ related mortality were tabulated. Evaluation of VE in the reduction of overall and HZ related mortality as per study objective was not performed due to low number of events reported.
Time frame: During the entire study period (3 to 5 year period following Day 0)
Number of Subjects With Confirmed HZ Episode Related Hospitalizations
Incidence of overall and HZ-related hospitalizations during the study.
Time frame: During the entire study period (3 to 5 year period following Day 0)
Number of Subjects With HZ Related Complications
Incidence of HZ complications during the study in subjects with confirmed HZ.
Time frame: During the entire study period (3 to 5 year period following Day 0)
Number of Subjects Receiving Pain Medication Associated With HZ
Incidence of use of pain medications throughout the study
Time frame: During the entire study period (3 to 5 year period following Day 0)
Number of Days With Pain Medication Associated With HZ
Incidence of reduction of duration of pain medication associated with HZ throughout the study.
Time frame: During the entire study period (3 to 5 year period following Day 0)
Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Occurrence, intensity of each solicited local symptom within 7 days (Days 0-6) after each vaccination, in subjects included in the 7-day diary card subset; Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = Significant pain at rest that prevented everyday normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Time frame: Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (including nausea, vomiting, diarrhea and/or abdominal pain), headache, myalgia, shivering and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Number of Subjects With Any, Grade 3 and Related Unsolicited Adverse Events (AEs)
Occurrence, intensity and relationship to vaccination of unsolicited AEs during 30 days (Days 0-29) after each vaccination, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification in all subjects. An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Time frame: Within the 30 days (Days 0-29) after each vaccination
Number of Subjects With Any and Related Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: From Month 0 to Month 14
Number of Subjects With Fatal Serious Adverse Events (SAEs)
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
Time frame: During the entire study period (3 to 5 year period following Day 0)
Number of Subjects With SAEs Related to Study Participation or Concomitant GSK Medication
The number of subjects with SAEs related to study participation or concomitant GSK medication were tabulated
Time frame: During the entire study period (3 to 5 year period following day 0)
Number of Subjects With Any and Related Potential Immune Mediated Diseases (pIMDs)
Occurrence and relationship to vaccination of any potential immune-mediated diseases (pIMDs) during the entire study period in all subjects
Time frame: During the entire study period (3 to 5 year period following Day 0)
Number of Subjects With Any and Related Medically Attended Visits
Occurrence and relationship to vaccination of medically attended visits other than routine health care visits, from Month 0 to Month 8 in all subjects. Medically attended visits were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any medically attended visits= Occurrence of any medically attended visits regardless of intensity grade or relation to vaccination.
Time frame: From Month 0 to Month 8 post-vaccination
Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Overall Number of Subjects With PHN in Subjects ≥ 50 YOA
Incidence of PHN calculated using the mTVc during the entire study period in subjects ≥ 50 YOA.
Time frame: During the entire study period (3 to 5 year period following Day 0)
Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With a Reduction of PHN Incidence in Subjects ≥ 50 YOA With Confirmed HZ
Occurrence of PHN during the entire study period in all subjects with confirmed HZ.
Time frame: During the entire study period (3 to 5 year period following Day 0)
Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With at Least One Day of Severe 'Worst' HZ-associated Pain in Subjects ≥ 70 YOA With Confirmed HZ.
The duration of severe 'worst' HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period was measured by the ZBPI in subjects ≥ 70 YOA with confirmed HZ .
Time frame: During the entire study period (3 to 5 year period following Day 0)
Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Duration of Severe 'Worst' HZ-associated Pain in Subjects ≥ 70 YOA With Confirmed HZ.
Duration of severe 'worst' HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period was measured by the ZBPI in subjects ≥ 70 YOA with confirmed HZ.
Time frame: During the entire study period (3 to 5 year period following Day 0)
Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any and Grade 3 Solicited Local Symptoms
Occurrence, intensity of each solicited local symptom within 7 days (Days 0-6) after each vaccination, in subjects ≥ 70 YOA. Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
Time frame: Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = Temperature\> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
Time frame: Within the 7-day (Days 0-6) post-vaccination period following each dose and across doses
Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any,Grade 3 and Related Unsolicited AEs in Subjects ≥ 70 YOA
Occurrence, intensity and relationship to vaccination of unsolicited AEs during 30 days (Days 0-29) after each vaccination, according to the MedDRA classification, in subjects ≥ 70 YOA.An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
Time frame: Within 30 days (Days 0 - 29) after each vaccination
Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any and Related SAEs
Occurrence and relationship to vaccination of all SAEs from Month 0 to Month 14 in subjects ≥ 70 YOA. Related SAEs also included any SAEs related to study participation or concurrent GSK medication/vaccine.
Time frame: From Month 0 to Month 14
Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Fatal SAEs
Fatal SAEs during the entire study period in subjects ≥ 70 YOA.
Time frame: During the entire study period (3 to 5 year period following Day 0)
Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any and Related pIMDs
Occurrence and relationship to vaccination of any pIMDs during the entire study period in subjects ≥ 70 YOA.
Time frame: During the entire study period (3 to 5 year period following Day 0)
Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Any and Related Medically Attended Visits
Occurrence and relationship to vaccination of medically attended visits (defined as hospitalizations, emergency room visits or visits to or from medical personnel), other than routine health care visits, from Month 0 to Month 8 in subjects ≥ 70 YOA.
Time frame: From Month 0 to Month 8 post-vaccination
| Milestone | Zoster-022 GSK1437173A Group | Zoster-022 Placebo Group |
|---|---|---|
| Started | 6950 | 6950 |
| Completed | 5770 | 5760 |
| Not completed | 1180 | 1190 |
| Withdrew: Serious adverse event | 456 | 487 |
| Withdrew: Non-serious adverse event | 47 | 15 |
| Withdrew: Protocol violation | 6 | 8 |
| Withdrew: Withdrawal by subject | 387 | 396 |
| Withdrew: Migrated/moved from study area | 51 | 46 |
| Withdrew: Lost to follow-up | 123 | 133 |
| Withdrew: Suspected hz episode | 2 | 2 |
| Withdrew: No reason from the subject | 108 | 102 |
| Withdrew: Unknown completion status | 0 | 1 |
Confirmed HZ cases during the study in the modified total vaccinated cohort (mTVc).
| Participants | Zoster-022 GSK1437173A 70-79YOA Group | Zoster-022 GSK1437173A >=80YOA Group | Zoster-022 GSK1437173A >=70YOA Group | Zoster-022 Placebo 70-79YOA Group | Zoster-022 Placebo >=80YOA Group | Zoster-022 Placebo >=70YOA Group |
|---|---|---|---|---|---|---|
| Number of Subjects With Any Episodes of Herpes Zoster (HZ) | 17 | 6 | 23 | 169 | 54 | 223 |
Incidence of PHN calculated using the mTVc during the entire study period in subjects ≥ 70 years of age (YOA).
| Participants | Zoster-022/006 Pooled GSK1437173A 70-79YOA Group | Zoster-022/006 Pooled GSK1437173A >=80YOA Group | Zoster-022/006 Pooled GSK1437173A >=70YOA Group | Zoster-022/006 Pooled Placebo 70-79YOA Group | Zoster-022/006 Pooled Placebo >=80YOA Group | Zoster-022/006 Pooled Placebo >=70YOA Group |
|---|---|---|---|---|---|---|
| Outcome Measure for the Pooled Analysis of Combined Data From Studies ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229): Number of Subjects With Post-herpetic Neuralgia (PHN) | 2 | 2 | 4 | 29 | 7 | 36 |
Occurrence of confirmed HZ during the entire study period in subjects ≥ 70 YOA.
| Participants | Zoster-022/006 Pooled GSK1437173A 70-79YOA Group | Zoster-022/006 Pooled GSK1437173A >=80YOA Group | Zoster-022/006 Pooled GSK1437173A >=70YOA Group | Zoster-022/006 Pooled Placebo 70-79YOA Group | Zoster-022/006 Pooled Placebo >=80YOA Group | Zoster-022/006 Pooled Placebo >=70YOA Group |
|---|---|---|---|---|---|---|
| Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Confirmed HZ | 19 | 6 | 25 | 216 | 68 | 284 |
PHN cases in the mTVc.
| Participants | Zoster-022 GSK1437173A 70-79YOA Group | Zoster-022 GSK1437173A >=80YOA Group | Zoster-022 GSK1437173A >=70YOA Group | Zoster-022 Placebo 70-79YOA Group | Zoster-022 Placebo >=80YOA Group | Zoster-022 Placebo >=70YOA Group |
|---|---|---|---|---|---|---|
| Number of Subjects With Post-herpetic Neuralgia (PHN) | 2 | 2 | 4 | 22 | 6 | 28 |
Duration of severe 'worst' HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period as measured by the Zoster Brief Pain Inventory (ZBPI) in subjects with confirmed HZ.
| Days | Zoster-022 GSK1437173A 70-79YOA Group | Zoster-022 GSK1437173A >=80YOA Group | Zoster-022 GSK1437173A >=70YOA Group | Zoster-022 Placebo 70-79YOA Group | Zoster-022 Placebo >=80YOA Group | Zoster-022 Placebo >=70YOA Group |
|---|---|---|---|---|---|---|
| Number of Days With Severe 'Worst' HZ-associated Pain | 21.8 ± 31.41 | 98.7 ± 57.73 | 34.6 ± 45.54 | 47.9 ± 100.08 | 50.4 ± 106.51 | 48.5 ± 101.40 |
The number of subjects with confirmed HZ related mortality and hospitalizations were tabulated.
| Participants | Zoster-022 GSK1437173A 70-79YOA Group | Zoster-022 GSK1437173A >=80YOA Group | Zoster-022 GSK1437173A >=70YOA Group | Zoster-022 Placebo 70-79YOA Group | Zoster-022 Placebo >=80YOA Group | Zoster-022 Placebo >=70YOA Group |
|---|---|---|---|---|---|---|
| Mortality | 0 | 0 | 0 | 0 | 0 | 0 |
| Hospitalization | 0 | 0 | 0 | 3 | 2 | 5 |
| Mortality or hospitalization | 0 | 0 | 0 | 3 | 2 | 5 |
The number of subjects with overall mortality and HZ related mortality were tabulated. Evaluation of VE in the reduction of overall and HZ related mortality as per study objective was not performed due to low number of events reported.
| Participants | Zoster-022 GSK1437173A 70-79YOA Group | Zoster-022 GSK1437173A >=80YOA Group | Zoster-022 GSK1437173A >=70YOA Group | Zoster-022 Placebo 70-79YOA Group | Zoster-022 Placebo >=80YOA Group | Zoster-022 Placebo >=70YOA Group |
|---|---|---|---|---|---|---|
| Number of Subjects With Overall Mortality and HZ-related Mortality | 0 | 0 | 0 | 0 | 0 | 0 |
Incidence of overall and HZ-related hospitalizations during the study.
| Participants | Zoster-022 GSK1437173A 70-79YOA Group | Zoster-022 GSK1437173A >=80YOA Group | Zoster-022 GSK1437173A >=70YOA Group | Zoster-022 Placebo 70-79YOA Group | Zoster-022 Placebo >=80YOA Group | Zoster-022 Placebo >=70YOA Group |
|---|---|---|---|---|---|---|
| Number of Subjects With Confirmed HZ Episode Related Hospitalizations | 0 | 0 | 0 | 3 | 2 | 5 |
Incidence of HZ complications during the study in subjects with confirmed HZ.
| Participants | Zoster-022 GSK1437173A 70-79YOA Group | Zoster-022 GSK1437173A >=80YOA Group | Zoster-022 GSK1437173A >=70YOA Group | Zoster-022 Placebo 70-79YOA Group | Zoster-022 Placebo >=80YOA Group | Zoster-022 Placebo >=70YOA Group |
|---|---|---|---|---|---|---|
| At least one complication | 1 | 0 | 1 | 6 | 4 | 10 |
| HZ vasculitis | 0 | 0 | 0 | 0 | 0 | 0 |
| Disseminated Disease | 0 | 0 | 0 | 0 | 2 | 2 |
| Ophthalmic Disease | 1 | 0 | 1 | 4 | 2 | 6 |
| Neurologic Disease | 0 | 0 | 0 | 3 | 0 | 3 |
| Visceral Disease | 0 | 0 | 0 | 0 | 0 | 0 |
| Stroke | 0 | 0 | 0 | 0 | 0 | 0 |
Incidence of use of pain medications throughout the study
| Participants | Zoster-022 GSK1437173A 70-79YOA Group | Zoster-022 GSK1437173A >=80YOA Group | Zoster-022 GSK1437173A >=70YOA Group | Zoster-022 Placebo 70-79YOA Group | Zoster-022 Placebo >=80YOA Group | Zoster-022 Placebo >=70YOA Group |
|---|---|---|---|---|---|---|
| At least 1 pain medication | 7 | 3 | 10 | 123 | 37 | 160 |
| 1 pain medication only | 5 | 0 | 5 | 43 | 17 | 60 |
| 2 pain medications only | 0 | 1 | 1 | 30 | 4 | 34 |
| 3 pain medications or more | 2 | 2 | 4 | 50 | 16 | 66 |
Incidence of reduction of duration of pain medication associated with HZ throughout the study.
| Days | Zoster-022 GSK1437173A 70-79YOA Group | Zoster-022 GSK1437173A >=80YOA Group | Zoster-022 GSK1437173A >=70YOA Group | Zoster-022 Placebo 70-79YOA Group | Zoster-022 Placebo >=80YOA Group | Zoster-022 Placebo >=70YOA Group |
|---|---|---|---|---|---|---|
| Number of Days With Pain Medication Associated With HZ | 38.7 ± 56.44 | 274.7 ± 337.00 | 109.5 ± 200.88 | 218.6 ± 593.80 | 135.0 ± 207.31 | 199.3 ± 530.60 |
Occurrence, intensity of each solicited local symptom within 7 days (Days 0-6) after each vaccination, in subjects included in the 7-day diary card subset; Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = Significant pain at rest that prevented everyday normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
| Participants | Zoster-022 GSK1437173A Group | Zoster-022 Placebo Group |
|---|---|---|
| Any Pain, Dose 1 | 297 | 26 |
| Grade 3 Pain, Dose 1 | 12 | 1 |
| Any Redness, Dose 1 | 143 | 3 |
| Grade 3 Redness, Dose 1 | 9 | 0 |
| Any Swelling, Dose 1 | 85 | 2 |
| Grade 3 Swelling, Dose 1 | 2 | 0 |
| Any Pain, Dose 2 | 282 | 23 |
| Grade 3 Pain, Dose 2 | 12 | 0 |
| Any Redness, Dose 2 | 137 | 3 |
| Grade 3 Redness, Dose 2 | 15 | 0 |
| Any Swelling, Dose 2 | 68 | 0 |
| Grade 3 Swelling, Dose 2 | 7 | 0 |
| Any Pain, Across Doses | 347 | 43 |
| Grade 3 Pain, Across Doses | 22 | 1 |
| Any Redness, Across Doses | 198 | 5 |
| Grade 3 Redness, Across Doses | 20 | 0 |
| Any Swelling, Across Doses | 114 | 2 |
| Grade 3 Swelling, Across Doses | 8 | 0 |
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (including nausea, vomiting, diarrhea and/or abdominal pain), headache, myalgia, shivering and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = fever \> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
| Participants | Zoster-022 GSK1437173A Group | Zoster-022 Placebo Group |
|---|---|---|
| Any Fatigue, Dose 1 | 104 | 56 |
| Grade 3 Fatigue, Dose 1 | 8 | 4 |
| Related Fatigue, Dose 1 | 85 | 34 |
| Any Gastrointestinal, Dose 1 | 25 | 28 |
| Grade 3 Gastrointestinal, Dose 1 | 3 | 2 |
| Related Gastrointestinal, Dose 1 | 16 | 14 |
| Any Headache, Dose 1 | 72 | 42 |
| Grade 3 Headache, Dose 1 | 2 | 4 |
| Related Headache, Dose 1 | 58 | 27 |
| Any Myalgia, Dose 1 | 106 | 27 |
| Grade 3 Myalgia, Dose 1 | 6 | 2 |
| Related Myalgia, Dose 1 | 91 | 16 |
| Any Shivering, Dose 1 | 38 | 17 |
| Grade 3 Shivering, Dose 1 | 1 | 1 |
| Related Shivering, Dose 1 | 32 | 12 |
| Any Temperature, Dose 1 | 39 | 9 |
| Grade 3 Temperature, Dose 1 | 0 | 2 |
| Related Temperature, Dose 1 | 31 | 4 |
| Any Fatigue, Dose 2 | 122 | 39 |
| Grade 3 Fatigue, Dose 2 | 9 | 0 |
| Related Fatigue, Dose 2 | 105 | 30 |
| Any Gastrointestinal, Dose 2 | 37 | 19 |
| Grade 3 Gastrointestinal, Dose 2 | 3 | 1 |
| Related Gastrointestinal, Dose 2 | 26 | 13 |
| Any Headache, Dose 2 | 76 | 26 |
| Grade 3 Headache, Dose 2 | 4 | 0 |
| Related Headache, Dose 2 | 63 | 20 |
| Any Myalgia, Dose 2 | 113 | 18 |
| Grade 3 Myalgia, Dose 2 | 7 | 0 |
| Related Myalgia, Dose 2 | 94 | 16 |
| Any Shivering, Dose 2 | 59 | 11 |
| Grade 3 Shivering, Dose 2 | 5 | 1 |
| Related Shivering, Dose 2 | 47 | 9 |
| Any Temperature, Dose 2 | 38 | 6 |
| Grade 3 Temperature, Dose 2 | 0 | 2 |
| Related Temperature, Dose 2 | 35 | 2 |
| Any Fatigue, Across Doses | 166 | 77 |
| Grade 3 Fatigue, Across Doses | 16 | 4 |
| Related Fatigue, Across Doses | 140 | 52 |
| Any Gastrointestinal, Across Doses | 55 | 40 |
| Grade 3 Gastrointestinal, Across Doses | 5 | 2 |
| Related Gastrointestinal, Across Doses | 38 | 21 |
| Any Headache, Across Doses | 124 | 55 |
| Grade 3 Headache, Across Doses | 5 | 4 |
| Related Headache, Across Doses | 104 | 37 |
| Any Myalgia, Across Doses | 157 | 41 |
| Grade 3 Myalgia, Across Doses | 12 | 2 |
| Related Myalgia, Across Doses | 137 | 29 |
| Any Shivering, Across Doses | 75 | 22 |
| Grade 3 Shivering, Across Doses | 6 | 2 |
| Related Shivering, Across Doses | 64 | 16 |
| Any Temperature, Across Doses | 62 | 13 |
| Grade 3 Temperature, Across Doses | 0 | 2 |
| Related Temperature, Across Doses | 54 | 6 |
Occurrence, intensity and relationship to vaccination of unsolicited AEs during 30 days (Days 0-29) after each vaccination, according to the Medical Dictionary for Regulatory Activities (MedDRA) classification in all subjects. An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
| Participants | Zoster-022 GSK1437173A Group | Zoster-022 Placebo Group |
|---|---|---|
| Any unsolicited AE(s) | 3859 | 2263 |
| Grade 3 unsolicited AE(s) | 485 | 265 |
| Related unsolicited AE(s) | 2853 | 529 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | Zoster-022 GSK1437173A Group | Zoster-022 Placebo Group |
|---|---|---|
| Any SAE(s) | 891 | 939 |
| Related SAE(s) | 12 | 7 |
Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.
| Participants | Zoster-022 GSK1437173A Group | Zoster-022 Placebo Group |
|---|---|---|
| Number of Subjects With Fatal Serious Adverse Events (SAEs) | 426 | 459 |
The number of subjects with SAEs related to study participation or concomitant GSK medication were tabulated
| Participants | Zoster-022 GSK1437173A Group | Zoster-022 Placebo Group |
|---|---|---|
| Number of Subjects With SAEs Related to Study Participation or Concomitant GSK Medication | 57 | 84 |
Occurrence and relationship to vaccination of any potential immune-mediated diseases (pIMDs) during the entire study period in all subjects
| Participants | Zoster-022 GSK1437173A Group | Zoster-022 Placebo Group |
|---|---|---|
| Any pIMD | 92 | 97 |
| Related pIMDs | 8 | 6 |
Occurrence and relationship to vaccination of medically attended visits other than routine health care visits, from Month 0 to Month 8 in all subjects. Medically attended visits were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any medically attended visits= Occurrence of any medically attended visits regardless of intensity grade or relation to vaccination.
| Participants | Zoster-022 GSK1437173A Group | Zoster-022 Placebo Group |
|---|---|---|
| Any medically attended visits | 2882 | 2911 |
| Related medically attended visits | 165 | 66 |
Incidence of PHN calculated using the mTVc during the entire study period in subjects ≥ 50 YOA.
| Participants | Zoster-022/006 Pooled GSK1437173A 50-59 YOA Group | Zoster-022/006 Pooled GSK1437173A 60-69 YOA Group | Zoster-022/006 Pooled GSK1437173A 70-79 YOA Group | Zoster-022/006 Pooled GSK1437173A >=80 YOA Group | Zoster-022/006 Pooled GSK1437173A >=50 YOA Group | Zoster-022/006 Pooled Placebo 50-59 YOA Group | Zoster-022/006 Pooled Placebo 60-69 YOA Group | Zoster-022/006 Pooled Placebo 70-79 YOA Group | Zoster-022/006 Pooled Placebo >=80 YOA Group | Zoster-022/006 Pooled Placebo >=50 YOA Group |
|---|---|---|---|---|---|---|---|---|---|---|
| Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Overall Number of Subjects With PHN in Subjects ≥ 50 YOA | 0 | 0 | 2 | 2 | 4 | 8 | 2 | 29 | 7 | 46 |
Occurrence of PHN during the entire study period in all subjects with confirmed HZ.
| Participants | Zoster-022/006 Pooled GSK1437173A 50-59 YOA Group | Zoster-022/006 Pooled GSK1437173A 60-69 YOA Group | Zoster-022/006 Pooled GSK1437173A 70-79 YOA Group | Zoster-022/006 Pooled GSK1437173A >=80 YOA Group | Zoster-022/006 Pooled GSK1437173A >=50 YOA Group | Zoster-022/006 Pooled Placebo 50-59 YOA Group | Zoster-022/006 Pooled Placebo 60-69 YOA Group | Zoster-022/006 Pooled Placebo 70-79 YOA Group | Zoster-022/006 Pooled Placebo >=80 YOA Group | Zoster-022/006 Pooled Placebo >=50 YOA Group |
|---|---|---|---|---|---|---|---|---|---|---|
| Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With a Reduction of PHN Incidence in Subjects ≥ 50 YOA With Confirmed HZ | 0 | 0 | 2 | 2 | 4 | 8 | 2 | 29 | 7 | 46 |
The duration of severe 'worst' HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period was measured by the ZBPI in subjects ≥ 70 YOA with confirmed HZ .
| Participants | Zoster-022/006 Pooled GSK1437173A 70-79 YOA Group | Zoster-022/006 Pooled GSK1437173A >=80 YOA Group | Zoster-022/006 Pooled GSK1437173A >=70 YOA Group | Zoster-022/006 Pooled Placebo 70-79 YOA Group | Zoster-022/006 Pooled Placebo >=80 YOA Group | Zoster-022/006 Pooled Placebo >=70 YOA Group |
|---|---|---|---|---|---|---|
| Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With at Least One Day of Severe 'Worst' HZ-associated Pain in Subjects ≥ 70 YOA With Confirmed HZ. | 17 | 3 | 20 | 193 | 61 | 254 |
Duration of severe 'worst' HZ-associated pain following the onset of a confirmed HZ rash over the entire pain reporting period was measured by the ZBPI in subjects ≥ 70 YOA with confirmed HZ.
| Days | Zoster-022/006 Pooled GSK1437173A 70-79 YOA Group | Zoster-022/006 Pooled GSK1437173A >=80 YOA Group | Zoster-022/006 Pooled GSK1437173A >=70 YOA Group | Zoster-022/006 Pooled Placebo 70-79 YOA Group | Zoster-022/006 Pooled Placebo >=80 YOA Group | Zoster-022/006 Pooled Placebo >=70 YOA Group |
|---|---|---|---|---|---|---|
| Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Duration of Severe 'Worst' HZ-associated Pain in Subjects ≥ 70 YOA With Confirmed HZ. | 20.3 ± 29.71 | 98.7 ± 57.73 | 32.1 ± 43.80 | 48.3 ± 96.34 | 45.2 ± 95.58 | 47.5 ± 95.98 |
Occurrence, intensity of each solicited local symptom within 7 days (Days 0-6) after each vaccination, in subjects ≥ 70 YOA. Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = pain that prevented normal activity. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.
| Participants | Zoster-022/006 Pooled GSK1437173A Group | Zoster-022/006 Pooled Placebo Group |
|---|---|---|
| Any Pain, Dose 1 | 1336 | 128 |
| Grade 3 Pain, Dose 1 | 42 | 1 |
| Any Redness, Dose 1 | 606 | 17 |
| Grade 3 Redness, Dose 1 | 43 | 0 |
| Any Swelling, Dose 1 | 355 | 17 |
| Grade 3 Swelling, Dose 1 | 17 | 0 |
| Any Pain, Dose 2 | 1241 | 107 |
| Grade 3 Pain, Dose 2 | 60 | 3 |
| Any Redness, Dose 2 | 582 | 14 |
| Grade 3 Redness, Dose 2 | 39 | 0 |
| Any Swelling, Dose 2 | 344 | 10 |
| Grade 3 Swelling, Dose 2 | 15 | 0 |
| Any Pain, Across Doses | 1562 | 199 |
| Grade 3 Pain, Across Doses | 90 | 4 |
| Any Redness, Across Doses | 851 | 27 |
| Grade 3 Redness, Across Doses | 70 | 0 |
| Any Swelling, Across Doses | 519 | 25 |
| Grade 3 Swelling, Across Doses | 30 | 0 |
Assessed solicited general symptoms were fatigue, gastrointestinal symptoms, headache, myalgia, shivering and fever \[defined as axillary temperature equal to or above 37.5 degrees Celsius (°C)\]. Any = occurrence of the symptom regardless of intensity grade. Grade 3 symptom = symptom that prevented normal activity. Grade 3 fever = Temperature\> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.
| Participants | Zoster-022/006 Pooled GSK1437173A Group | Zoster-022/006 Pooled Placebo Group |
|---|---|---|
| Any Fatigue, Dose 1 | 545 | 231 |
| Grade 3 Fatigue, Dose 1 | 31 | 13 |
| Related Fatigue, Dose 1 | 441 | 147 |
| Any Gastrointestinal, Dose 1 | 170 | 123 |
| Grade 3 Gastrointestinal, Dose 1 | 15 | 6 |
| Related Gastrointestinal, Dose 1 | 101 | 67 |
| Any Headache, Dose 1 | 380 | 189 |
| Grade 3 Headache, Dose 1 | 7 | 8 |
| Related Headache, Dose 1 | 293 | 132 |
| Any Myalgia, Dose 1 | 530 | 159 |
| Grade 3 Myalgia, Dose 1 | 26 | 7 |
| Related Myalgia, Dose 1 | 445 | 101 |
| Any Shivering, Dose 1 | 206 | 73 |
| Grade 3 Shivering, Dose 1 | 15 | 3 |
| Related Shivering, Dose 1 | 173 | 50 |
| Any Temperature, Dose 1 | 142 | 34 |
| Grade 3 Temperature, Dose 1 | 1 | 2 |
| Related Temperature, Dose 1 | 111 | 16 |
| Any Fatigue, Dose 2 | 579 | 169 |
| Grade 3 Fatigue, Dose 2 | 53 | 4 |
| Related Fatigue, Dose 2 | 495 | 116 |
| Any Gastrointestinal, Dose 2 | 188 | 75 |
| Grade 3 Gastrointestinal, Dose 2 | 14 | 5 |
| Related Gastrointestinal, Dose 2 | 142 | 35 |
| Any Headache, Dose 2 | 455 | 133 |
| Grade 3 Headache, Dose 2 | 30 | 2 |
| Related Headache, Dose 2 | 386 | 86 |
| Any Myalgia, Dose 2 | 560 | 112 |
| Grade 3 Myalgia, Dose 2 | 42 | 4 |
| Related Myalgia, Dose 2 | 484 | 75 |
| Any Shivering, Dose 2 | 334 | 55 |
| Grade 3 Shivering, Dose 2 | 36 | 4 |
| Related Shivering, Dose 2 | 292 | 34 |
| Any Temperature, Dose 2 | 224 | 30 |
| Grade 3 Temperature, Dose 2 | 2 | 3 |
| Related Temperature, Dose 2 | 189 | 14 |
| Any Fatigue, Across Doses | 825 | 326 |
| Grade 3 Fatigue, Across Doses | 79 | 17 |
| Related Fatigue, Across Doses | 699 | 220 |
| Any Gastrointestinal, Across Doses | 304 | 172 |
| Grade 3 Gastrointestinal,Across Doses | 26 | 10 |
| Related Gastrointestinal,Across Doses | 210 | 91 |
| Any Headache, Across Doses | 653 | 268 |
| Grade 3 Headache, Across Doses | 34 | 10 |
| Related Headache, Across Doses | 547 | 185 |
| Any Myalgia, Across Doses | 790 | 225 |
| Grade 3 Myalgia, Across Doses | 62 | 10 |
| Related Myalgia, Across Doses | 689 | 157 |
| Any Shivering, Across Doses | 439 | 110 |
| Grade 3 Shivering, Across Doses | 49 | 6 |
| Related Shivering, Across Doses | 380 | 75 |
| Any Temperature, Across Doses | 323 | 61 |
| Grade 3 Temperature, Across Doses | 3 | 3 |
| Related Temperature, Across Doses | 265 | 30 |
Occurrence, intensity and relationship to vaccination of unsolicited AEs during 30 days (Days 0-29) after each vaccination, according to the MedDRA classification, in subjects ≥ 70 YOA.An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination. Grade 3 AE = an AE which prevented normal, everyday activities. Related = AE assessed by the investigator as related to the vaccination.
| Participants | Zoster-022/006 Pooled GSK1437173A Group | Zoster-022/006 Pooled Placebo Group |
|---|---|---|
| Any unsolicited AE(s) | 4366 | 2732 |
| Grade 3 unsolicited AE(s) | 553 | 335 |
| Related unsolicited AE(s) | 2961 | 578 |
Occurrence and relationship to vaccination of all SAEs from Month 0 to Month 14 in subjects ≥ 70 YOA. Related SAEs also included any SAEs related to study participation or concurrent GSK medication/vaccine.
| Participants | Zoster-022/006 Pooled GSK1437173A Group | Zoster-022/006 Pooled Placebo Group |
|---|---|---|
| Any SAE(s) | 1117 | 1171 |
| Related SAE(s) | 12 | 7 |
Fatal SAEs during the entire study period in subjects ≥ 70 YOA.
| Participants | Zoster-022/006 Pooled GSK1437173A Group | Zoster-022/006 Pooled Placebo Group |
|---|---|---|
| Outcome Measure for the Pooled Analysis of Combined Data From Studies Zoster-006 (NCT01165177) and Zoster-022 (NCT01165229): Number of Subjects With Fatal SAEs | 128 | 144 |
Occurrence and relationship to vaccination of any pIMDs during the entire study period in subjects ≥ 70 YOA.
| Participants | Zoster-022/006 Pooled GSK1437173A Group | Zoster-022/006 Pooled Placebo Group |
|---|---|---|
| Any pIMD(s) | 110 | 118 |
| Related pIMD(s) | 8 | 8 |
Occurrence and relationship to vaccination of medically attended visits (defined as hospitalizations, emergency room visits or visits to or from medical personnel), other than routine health care visits, from Month 0 to Month 8 in subjects ≥ 70 YOA.
| Participants | Zoster-022/006 Pooled GSK1437173A Group | Zoster-022/006 Pooled Placebo Group |
|---|---|---|
| Any medically attended visits | 3593 | 3648 |
| Related medically attended visits | 180 | 80 |
Collected over Solicited symptoms: within 7 days (Days 0-6) after vaccination; Unsolicited adverse events: within 30 days (Days 0-29) after vaccination; Serious Adverse Events (SAEs): during the entire study period (3 to 5 year period following Day 0).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Zoster-022 GSK1437173A Group | 426/6,950 (6.1%) | 1,153/6,950 (16.6%) | 3,067/6,950 (44.1%) |
| Zoster-022 Placebo Group | 459/6,950 (6.6%) | 1,214/6,950 (17.5%) | 610/6,950 (8.8%) |
| Event | Zoster-022 GSK1437173A Group | Zoster-022 Placebo Group |
|---|---|---|
| PneumoniaInfections and infestations | 70/6950 | 81/6950 |
| Cardiac failureCardiac disorders | 51/6950 | 57/6950 |
| Atrial fibrillationCardiac disorders | 40/6950 | 54/6950 |
| Myocardial infarctionCardiac disorders | 41/6950 | 45/6950 |
| Cerebrovascular accidentNervous system disorders | 34/6950 | 31/6950 |
| Cardiac failure congestiveCardiac disorders | 23/6950 | 33/6950 |
| DeathGeneral disorders | 17/6950 | 29/6950 |
| Acute myocardial infarctionCardiac disorders | 21/6950 | 28/6950 |
| Coronary artery diseaseCardiac disorders | 28/6950 | 25/6950 |
| Urinary tract infectionInfections and infestations | 28/6950 | 24/6950 |
| Event | Zoster-022 GSK1437173A Group | Zoster-022 Placebo Group |
|---|---|---|
| Injection site painGeneral disorders | 1975/6950 | 148/6950 |
| Injection site erythemaGeneral disorders | 864/6950 | 27/6950 |
| Injection site swellingGeneral disorders | 613/6950 | 16/6950 |
| HeadacheNervous system disorders | 586/6950 | 243/6950 |
| PyrexiaGeneral disorders | 535/6950 | 52/6950 |
| FatigueGeneral disorders | 474/6950 | 169/6950 |
| PainGeneral disorders | 428/6950 | 60/6950 |
| MyalgiaMusculoskeletal and connective tissue disorders | 378/6950 | 99/6950 |
| ChillsGeneral disorders | 353/6950 | 39/6950 |
| Age, Continuous(Years) | Zoster-022 GSK1437173A Group | Zoster-022 Placebo Group | Total |
|---|---|---|---|
| Mean | 75.6 ± 4.7 | 75.6 ± 4.7 | 75.6 ± 4.7 |
| Sex: Female, Male(Participants) | Zoster-022 GSK1437173A Group | Zoster-022 Placebo Group | Total |
|---|---|---|---|
| Female | 3789 | 3836 | 7625 |
| Male | 3161 | 3114 | 6275 |
| Race/Ethnicity, Customized(Participants) | Zoster-022 GSK1437173A Group | Zoster-022 Placebo Group | Total |
|---|---|---|---|
| Geographic ancestry — African Heritage / African American | 79 | 67 | 146 |
| Geographic ancestry — American Indian or Alaskan Native | 1 | 8 | 9 |
| Geographic ancestry — Asian - Central/South Asian Heritage | 3 | 6 | 9 |
| Geographic ancestry — Asian - East Asian Heritage | 907 | 908 | 1815 |
| Geographic ancestry — Asian - Japanese Heritage | 298 | 300 | 598 |
| Geographic ancestry — Asian - South East Asian Heritage | 8 | 4 | 12 |
| Geographic ancestry — Native Hawaiian or Other Pacific Islander | 3 | 3 | 6 |
| Geographic ancestry — White - Arabic / North African Heritage | 40 | 47 | 87 |
| Geographic ancestry — White - Caucasian / European Heritage | 5307 | 5301 | 10608 |
| Geographic ancestry — Other | 304 | 306 | 610 |
Showing the first 100 of 213 sites across 18 countries. Choose a country and city above to see the rest.
Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: IPD is available via the Clinical Study Data Request site (click on the link provided below)
Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.
Data sharing details ↗ · clinicalstudydatarequest.com
Ran from Aug 2010 to primary completion in Jul 2015, 59 months.
Results were first posted in Nov 2017, 2 years 3 months after primary completion. A results delay was requested in Aug 2013.
Of 33 industry-sponsored phase 3 interventional studies under Herpes Zoster, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 45. This study's 59 months is above that.
Counting every sponsor, half of 40 studies reached it within 16 months; a quarter within 10 and three quarters within 45.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Shingrix